Dr. C. Jimmy Lin
C. Jimmy Lin,
M.D., Ph.D., MHS is
Founder of the
Rare Genomics Institute (RGI) and
Research Instructor, Genomics and Pathology Services,
Washington University School of Medicine in St. Louis.
The Rare Genomics Institute helps patients to crowdsource funds and genomes to accelerate research of their rare genetic diseases. They are a community dedicated to helping rare disease patients find hope for a cure. RGI works alongside patients and their families, providing them with the necessary tools, knowledge, and connections so that patients can better understand the cause of their disease. They believe that every patient deserves more out of life.
Previously Jimmy was the the lead computational biologist for the ground-breaking cancer genome sequencing efforts from the Vogelstein Lab at Johns Hopkins. Their sequencing of the first 100+ cancer exomes in 5 different tissue types helped lay the foundation for a revolution in cancer genomics.
His papers include The Genomic Landscapes of Human Breast and Colorectal Cancers, The Consensus Coding Sequences of Human Breast and Colorectal Cancers, The genetic landscape of the childhood cancer medulloblastoma, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, An integrated genomic analysis of human glioblastoma multiforme, Exome sequencing identifies GRIN2A as frequently mutated in melanoma, and Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Jimmy earned his BA/BS in Cognitive Science, Molecular Biochemistry & Biophysics at Yale University in 2001. He earned his MHS in Bioinformatics at Johns Hopkins University in 2011. He earned his M.D. and Ph.D. at The Johns Hopkins University School of Medicine in 2012.
Watch Dr. Jimmy Lin — Game-Changing Paradigms for Rare Diseases and Disruptive Heroes, C. Jimmy Lin. Read Turning point: Jimmy Lin. Read Curing Cancer Relies on Genome Mapping With DNA Evidence Guiding Treatment. View his Facebook page. Read his Google+ profile, LinkedIn profile, and his TED profile. Follow his Twitter feed.